Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2009 Dec 15;73(24):2061-70.
doi: 10.1212/WNL.0b013e3181c67808. Epub 2009 Nov 18.

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

S Salloway  1 , R Sperling, S Gilman, N C Fox, K Blennow, M Raskind, M Sabbagh, L S Honig, R Doody, C H van Dyck, R Mulnard, J Barakos, K M Gregg, E Liu, I Lieberburg, D Schenk, R Black, M Grundman; Bapineuzumab 201 Clinical Trial Investigators
Affiliations
Clinical Trial

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

S Salloway et al. Neurology. .

Abstract

Background: Bapineuzumab, a humanized anti-amyloid-beta (Abeta) monoclonal antibody for the potential treatment of Alzheimer disease (AD), was evaluated in a multiple ascending dose, safety, and efficacy study in mild to moderate AD.

Methods: The study enrolled 234 patients, randomly assigned to IV bapineuzumab or placebo in 4 dose cohorts (0.15, 0.5, 1.0, or 2.0 mg/kg). Patients received 6 infusions, 13 weeks apart, with final assessments at week 78. The prespecified primary efficacy analysis in the modified intent-to-treat population assumed linear decline and compared treatment differences within dose cohorts on the Alzheimer's Disease Assessment Scale-Cognitive and Disability Assessment for Dementia. Exploratory analyses combined dose cohorts and did not assume a specific pattern of decline.

Results: No significant differences were found in the primary efficacy analysis. Exploratory analyses showed potential treatment differences (p < 0.05, unadjusted for multiple comparisons) on cognitive and functional endpoints in study "completers" and APOE epsilon4 noncarriers. Reversible vasogenic edema, detected on brain MRI in 12/124 (9.7%) bapineuzumab-treated patients, was more frequent in higher dose groups and APOE epsilon4 carriers. Six vasogenic edema patients were asymptomatic; 6 experienced transient symptoms.

Conclusions: Primary efficacy outcomes in this phase 2 trial were not significant. Potential treatment differences in the exploratory analyses support further investigation of bapineuzumab in phase 3 with special attention to APOE epsilon4 carrier status.

Classification of evidence: Due to varying doses and a lack of statistical precision, this Class II ascending dose trial provides insufficient evidence to support or refute a benefit of bapineuzumab.

PubMed Disclaimer

Figures

None
Figure 1 Patient disposition
None
Figure 2 Estimated mean change from baseline over time on Alzheimer's Disease Assessment Scale–Cognitive subscale (ADAS-Cog) and Disability Assessment for Dementia (DAD) for the 4 combined dose cohorts in the modified intent-to-treat (mITT) and completer populations Error bars represent one standard error. A positive change from baseline represents improvement. The p values are not adjusted for multiple comparisons. (A) ADAS-Cog, mITT; (B) ADAS-Cog, completers; (C) DAD, mITT; (D) DAD, completers.
None
Figure 3 Serial MRI scans (fluid-attenuated inversion recovery) in a patient with vasogenic edema (VE) This 69-year-old woman is an APOE ε4 homozygote who was treated with bapineuzumab 1.0 mg/kg IV. She remained asymptomatic despite the appearance of multiple areas of VE evident on the MRI. The VE was apparent on MRI by 7 weeks after her first infusion and resolved by 19 weeks. The patient was redosed at 0.5 mg/kg of bapineuzumab IV and followed for over 2 years without recurrence of VE.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Selkoe DJ, Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 2003;43:545–584. - PubMed
    1. Schroeter S, Khan K, Barbour R, et al. Immunotherapy reduces vascular amyloid-beta in PDAPP mice. J Neurosci 2008;28:6787–6793. - PMC - PubMed
    1. Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000;6:916–919. - PubMed
    1. Buttini M, Masliah E, Barbour R, et al. Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. J Neurosci 2005;25:9096–9101. - PMC - PubMed
    1. Shankar GM, Li S, Mehta TH, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008;14:837–842. - PMC - PubMed

Publication types

MeSH terms

Grants and funding